Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Eur Neuropsychopharmacol. 2011 Dec;21(12):861-6. doi: 10.1016/j.euroneuro.2011.03.004. Epub 2011 Apr 5.
There is as yet no definite prognostic marker to determine whether a first-episode psychosis will become schizophrenia or not. The aim of the present study is to address whether the mechanism of sensitization of the subcortical dopaminergic pathway - yielding to an increase of the postsynaptic D2 receptors - may serve as a prognostic marker of clinical outcome in drug naïve patients with a first-episode psychosis, by means of a prospective and multicentric study with untreated first-episode psychosis patients (n=37). 123I-IBZM SPECT was performed at the time of the inclusion in the study, before antipsychotic medication was initiated. One year later, patients were assessed again so as to determine their diagnosis. There was a significant group effect at baseline in D2 Striatal/Frontal (S/F) ratios (F=10.2, p<0.001). Bonferroni posthoc comparisons attested significant differences between diagnosis (p=0.006), and between schizophrenia and control groups (p<0.001) but no differences between non-schizophrenia and control groups (p=0.9). The logistic regression model showed that D2R binding (p=0.02) and PAS (Premorbid Adjustment Scale) adulthood score (p=0.03) were predictive of the final diagnosis (schizophrenia/non-schizophrenia; Nagelkerke R(2)=0.59; X(2)=11.08, p=0.001). These findings replicate previous results on the usefulness of D2R binding as an objective prognostic parameter, together with the evaluation of premorbid adjustment, of the evolution of first-episode psychosis. In this regard, the results may provide a new view in the approach of early and personalized treatment in the debut of a psychosis.
目前尚无明确的预后标志物来确定首发精神病是否会发展为精神分裂症。本研究旨在探讨皮质下多巴胺能通路的敏化机制——导致突触后 D2 受体增加——是否可以作为未经药物治疗的首发精神病患者临床结局的预后标志物,通过一项前瞻性、多中心研究,对未经药物治疗的首发精神病患者(n=37)进行研究。在开始使用抗精神病药物之前,在纳入研究时进行 123I-IBZM SPECT 检查。一年后,再次对患者进行评估以确定其诊断。在 D2 纹状体/额叶(S/F)比值上,基线时有显著的组间差异(F=10.2,p<0.001)。Bonferroni 事后比较证实了诊断之间的显著差异(p=0.006),以及精神分裂症组与对照组之间的显著差异(p<0.001),而非精神分裂症组与对照组之间无差异(p=0.9)。逻辑回归模型显示,D2R 结合(p=0.02)和 PAS(发病前调整量表)成年期评分(p=0.03)是最终诊断(精神分裂症/非精神分裂症)的预测因子(Nagelkerke R(2)=0.59;X(2)=11.08,p=0.001)。这些发现复制了之前关于 D2R 结合作为客观预后参数的有用性的结果,以及对发病前调整的评估,对首发精神病的演变。在这方面,这些结果可能为早期和个体化治疗精神疾病的新方法提供了新的视角。